W. Amick

Transport Pharmaceuticals, Inc. engaged in the development of medical products for the treatment of multiple dermatological diseases. It developed iontophoretic technique to effect trans-dermal drug delivery for a number of dermatological conditions. The company was founded by Dennis I. Goldberg in 1999 and was headquartered in Framingham, MA.

Biolex Therapeutics, Inc. developed and produced drugs. The company was founded in 1997 and was headquartered in Pittsboro, NC.

BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA.

Argolyn Bioscience, Inc. discovers and develops therapeutic products. It uses amino acid analog substitution technology to enable discovery of novel drug candidates. The firm's products pipeline include library construction, lead identification, and preclinical & clinical development. The company was founded by Thomas A. Dix in May 2002 and is headquartered in Durham, NC.

Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina.

Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC.

Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey.

Part of Johnson & Johnson, Janssen-Cilag International NV is a Belgian company that develops novel medicines and solutions. Bart Willem van Zijll Langhout has been the CEO of the company since 2009.